A phase 1 trial in Nature Medicine found a personalised neoantigen vaccine called NeoVax, combined with nivolumab, was feasible and acceptably safe in platinum-sensitive ovarian cancer.
Trending
- Saturn Pulls Further Ahead With 128 Newly Confirmed Moons
- Personalised Cancer Vaccine Shows Early Promise in Ovarian Trial
- Cara Memilih situs slot Terpercaya dan Aman di Indonesia
- Electrical Issues Addressed by Electric Dryer Repair Round Rock TX Experts
- SpaceX Launch Creates Stunning Jellyfish Cloud Over US East Coast
- Continuous Glucose Monitors Help Type 2 Diabetes Patients Stay in Range Longer
- A Beginner’s Guide to Exploring BDG NET
- The Quiet Comeback of Local News: Why Community Journalism Is Winning Readers Back
